

1 Time-resolved metabolic footprinting for non-linear modelling of
2 bacterial substrate utilization

3

4 Volker Behrends^{1,2}, Tim MD Ebbels¹, Huw D Williams², Jacob G Bundy^{1*}

5

6 1: Imperial College London, Department of Biomolecular Medicine, Division of
7 Surgery, Oncology, Reproductive Biology, and Anaesthetics, Faculty of Medicine, Sir
8 Alexander Fleming Building, London SW7 2AZ, UK

9

10 2: Imperial College London, Department of Life Sciences, Division of Biology, Faculty
11 of Natural Sciences, Sir Alexander Fleming Building, London SW7 2AZ, UK

12

13 *Corresponding author.

14 Email: j.bundy@imperial.ac.uk

15 Telephone: +44 20 75943039

16 Fax: +44 20 75943226

17

18 Running title: Time-resolved metabolic footprinting

19

20 Keywords: metabolomics, *Pseudomonas aeruginosa*, *Burkholderia cepacia* complex,
21 *Escherichia coli*, metabolic footprinting, exometabolome, cystic fibrosis

22

1 ABSTRACT

2 Untargeted profiling of small molecule metabolites from microbial culture
3 supernatants (metabolic footprinting) has great potential as a phenotyping tool. We
4 employed time-resolved metabolic footprinting to compare one *Escherichia coli* and
5 three *Pseudomonas aeruginosa* strains growing on complex media and showed that
6 considering metabolite changes over the whole course of growth provides much
7 more information than taking a single time-point. Most strikingly, there was
8 pronounced selectivity in metabolite uptake, even when the bacteria were growing
9 apparently exponentially, with certain groups of metabolites not taken up until others
10 had been entirely depleted from the medium. Additionally, metabolite excretion
11 showed some complex patterns. Fitting non-linear equations (four-parameter
12 sigmoids) to individual metabolite data allowed us to model these changes for
13 metabolite uptake, and visualize them by back-projecting the curve-fit parameters
14 onto the original growth curves. These 'uptake window' plots clearly demonstrated
15 strain differences, with the uptake of some compounds being reversed in order
16 between different strains. Comparison of an undefined rich medium (LB) with a
17 defined complex medium designed to mimic cystic fibrosis sputum showed many
18 differences, both qualitative and quantitative, with a greater proportion of excreted to
19 utilized metabolites in the defined medium. Extending the strain comparison to a
20 more closely related set of isolates showed it was possible to discriminate two
21 species of the *Burkholderia cepacia* complex based on uptake dynamics alone. We
22 believe time-resolved metabolic footprinting could be a valuable tool for many
23 questions in bacteriology, including isolate comparisons, phenotyping deletion
24 mutants, and as a functional complement to taxonomic classifications.

1 INTRODUCTION

2

3 The increasing speed of gene discovery has exceeded our ability to understand gene
4 function, and one of the bottlenecks is the need for new, high throughput tools to
5 evaluate cellular phenotypes (22). Even in bacterial genomes less than 70% of genes
6 have an assigned putative function and fewer still are characterized biochemically.
7 Metabolic profiling approaches have shown great promise for providing these tools
8 for functional genomics and hypothesis generation (1, 6, 10, 18, 28, 43, 49), because
9 they offer complementary information to transcriptomics and proteomics, in particular
10 giving an integrated picture of information downstream of the genome (51). Various
11 aspects of cellular physiology like the levels of transcripts, proteins or protein activity
12 are altered in response to environmental cues or metabolite concentrations
13 themselves. In return, these changes are amplified in the metabolome to give an
14 accumulated – and highly sensitive – description of the physiological state of the
15 organism or cellular compartment (26, 45, 49). This extends to natural populations
16 that have multiple uncharacterized genetic changes such as an accumulation of
17 mutations, as well as sometimes-extensive genetic differences like pathogenicity
18 islands (21), which may interact to give complex phenotypes. Molecular phylogenetic
19 methods based on gene sequences have proved successful in classifying bacteria
20 into taxonomic groupings, but these may not always correspond to easily identifiable
21 pheno- or ecotypes (29, 33, 48). Hence additional methods for strain assessment
22 that could be related to function would still be valuable.

23

24 Metabolomics gives an integrated measurement of cellular phenotype, and is highly
25 suited to quantitative analysis and description. In a microbial context, metabolomics

1 offers the additional advantage that there is only a single cell type, and little
2 compartmentation (at least in comparison to the equivalent problem in a multicellular
3 organism). However, sampling intracellular metabolites without either changing their
4 relative concentrations or introducing contamination from supernatant metabolites is
5 not straightforward, and research methods are still under active development by
6 different groups (7, 12, 15, 59, 62). In contrast, exometabolome or supernatant
7 profiling ('metabolic footprinting') is simple, and extracellular metabolites can exhibit
8 very large changes in pool size (1, 27, 40, 45). These multiple advantages mean that
9 exometabolome analysis has already been employed for a number of diverse
10 applications, such as phenotyping of both single-gene deletion mutants as well as
11 isolates from natural populations, although so far mostly for fungi rather than bacteria
12 (1, 2, 9, 25, 40, 48).

13

14 Because metabolism integrates information from gene expression and a wealth of
15 environmental cues, each organism will exhibit a distinct response, i.e. metabolic
16 pattern that takes into account all these factors. It is therefore unsurprising that these
17 patterns change with growth phase (1, 30). Despite this fact, it is currently common
18 practice to sample only at one or two time-points, mostly the end of growth, in
19 stationary phase (e.g. 48) and/or in mid-exponential phase (41, 52). In contrast, there
20 is ample evidence that cellular biochemistry changes during growth (1, 3, 8, 39).
21 Vertebrate studies have shown that explicitly considering 'through time' responses
22 (metabolic trajectories) adds considerably to the description and understanding of
23 biological events (16, 23, 58). We therefore argue that new approaches that are
24 capable of integrating metabolic phenotypes over a range of conditions could be
25 extremely beneficial for microbiology.

1

2 In this study we have developed such an approach and evaluated it by monitoring
3 metabolic changes over the course of time in growing batch cultures. Time Resolved
4 Metabolic Footprinting (TReF) was used to compare the well-studied organisms
5 *Escherichia coli* and *Pseudomonas aeruginosa*. We demonstrate that TReF is
6 considerably more data-rich and informative than sampling at single time points and
7 show the usefulness of the approach in hypothesis generation and as a phenotyping
8 tool. We also show that TReF distinguishes isolates from the closely related
9 *Burkholderia cepacia* complex (Bcc) at the species level for *B. cepacia* and *B.*
10 *cenocepacia*, which is not the case for single timepoint analysis. The approach is
11 very general and would therefore benefit the broader application of metabolomics to
12 bacterial systems.

13

1 MATERIALS AND METHODS

2 **Bacterial strains.** We used the following strains in this study: *Escherichia coli*
3 MG1655; the *Pseudomonas aeruginosa* wild type strains PA01 and PA14 (50), *P.*
4 *aeruginosa* PA0381 *leu-38 str-2*, a leucine auxotroph derived from PA01 (17);
5 *B. cenocepacia* LMG 16654, *B. cenocepacia* LMG 16659, *B. cenocepacia* LMG
6 18830, *B. cenocepacia* LMG 16656 (J2315), *B. cenocepacia* LMG 18863, *B. cepacia*
7 LMG, *B. cepacia* LMG 6963, *B. cepacia* LMG 6988, and *B. cepacia* LMG 18821.
8 Starter cultures for four biological replicates were set up by inoculating single
9 colonies into 5 ml of LB medium (10 g/L tryptone, 5 g yeast extract, 5 g NaCl) and
10 growing overnight at 37°C, shaking at 150 rpm. The growth of PA01 was compared
11 under the same conditions in synthetic cystic fibrosis medium (SCFM), a complex
12 defined medium designed to model nutrient status in sputum (46). These cultures
13 were used to inoculate 20 ml of LB or SCFM in 250 ml conical flasks and then grown
14 for 24 h at 37°C shaking at 150 rpm.

15
16 **Sampling:** 1 ml was taken from the culture at 0, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, and 24
17 hours for *E. coli*, *P. aeruginosa* PA01 and all *Burkholderia* strains. The *P. aeruginosa*
18 PA14 and *P. aeruginosa* PA0381 cultures were sampled at 0, 2, 3, 4, 5, 6, 8, 10, 12,
19 14, 16, and 24 hours. (It should be noted that the total volumes sampled from each
20 culture would potentially change the cell physiology in comparison to an unsampled
21 flask; however, we were not aiming to model an unsampled culture.) For each
22 sample, 0.1 ml was mixed with 0.9 ml culture medium for determination of cell
23 density (OD₆₀₀). The remainder of the sample was centrifuged (16000 x *g*, RT) and
24 0.75 ml of the supernatant mixed with 0.2 ml NMR buffer (25 mM sodium azide, 0.25
25 M phosphate buffer pH 7, and 5 mM sodium 3-trimethylsilyl-2,2,3,3-²H₄-propionate

1 (TSP), in $^2\text{H}_2\text{O}$). The $^2\text{H}_2\text{O}$ provided a field frequency lock for the spectrometer and
2 the TSP served as an internal chemical shift reference.

3

4 **^1H NMR measurement:** spectra were acquired on a Bruker Avance DRX600 NMR
5 spectrometer (Bruker BioSpin, Rheinstetten, Germany), with a magnetic field
6 strength of 14.1 T and resulting ^1H resonance frequency of 600 MHz, equipped with
7 a 5 mm inverse flow probe. Samples were introduced using a Gilson flow-injection
8 autosampler. Spectra were acquired following the approach given in (4). Briefly, a
9 one-dimensional NOESY pulse sequence was used for water suppression; data were
10 acquired into 32 K data points over a spectral width of 12 kHz, with 8 dummy scans
11 and 64 scans per sample, and an additional longitudinal relaxation recovery delay of
12 3.5 s per scan, giving a total recycle time of 5 s.

13

14 **Spectral processing and data analysis:** Spectra were processed in iNMR 2.5
15 (Nucleomatica, Molfetta, Italy). Free induction decays were multiplied by an
16 exponential apodization function equivalent to 0.5 Hz line broadening, followed by
17 Fourier transformation. Spectra were manually phased and automated first order
18 baseline correction was applied. Spectral data between -0.5 and 10 ppm were then
19 imported into Matlab 2007b (MathWorks, Cambridge, UK) and normalized to the
20 integral of the TSP signal. Metabolites were assigned using in-house data, the
21 Chenomx NMR Suite 3.1 (Chenomx Inc., Edmonton, Canada) and the Biological
22 Magnetic Resonance Databank metabolomics database (14). Signature peaks, i.e.
23 well-resolved resonances that could be easily assigned to one compound, were
24 identified from the spectra. Difference spectra were calculated in order to eliminate
25 the influence of (non-biological) variation in media composition. For this, the

1 spectrum at time-point 0 h was subtracted from the spectra of other time-points of the
2 same strain-replicate pair (i.e. all spectra sampled from the same flask). In addition to
3 full resolution spectra, all analyses were carried out on spectra binned integrals
4 representing the dominant resonances detected in fresh, non-inoculated medium.
5 153 integrals were fitted for LB, and 130 for SCFM. For the heatmap plots, the overall
6 range of the resonance intensity changes was set to one and the changes were
7 expressed relative to the starting values.

8

9 **Modeling and pattern recognition analysis**

10 We tested two different approaches to monitor the time-dependent changes in
11 metabolite concentration: (a) Linear regression analysis was carried out with both
12 optical density at 600 nm (OD) and time as X variable. A cut-off value for goodness
13 of fit ($R^2=0.6$) was determined by visual inspection of the fits. (b) Non-linear
14 regression of the data against time using a sigmoid curve model (Eq. 1) was carried
15 out using 'nlinfit' (Matlab statistics toolbox, Matlab). This resulted in fitting each
16 variable with four parameters, the amplitude of the curve, the 'half-life' (t_{50}) and the
17 width of the decrease. Cut-offs for t_{50} (1-24 h), width (0-12 h) and relative error
18 (< 0.6) were imposed.

$$19 \quad y = \frac{\mathit{amplitude}}{1 + e^{-\frac{x - (t_{50})}{\mathit{width}}}} + \mathit{offset} \quad [1]$$

20

21 The width is defined as the time that elapses for the exponent of e to go from 1 to -1.
22 Growth rate differences (*E. coli* grows faster than the *Pseudomonas* strains) manifest
23 themselves in higher t_{50} values for slower growing than faster growing strains, and
24 these quantitative growth rate effects complicate the elucidation of qualitative

1 differences that are particularly interesting for strain comparison purposes. Therefore,
2 the sigmoid parameters were corrected for growth-curve bias before pattern
3 recognition: the OD values were also fitted to the same non-linear model (Eq. 1). The
4 amplitude was divided by the amplitude of the OD, and the t_{50} was expressed relative
5 to the t_{50} of the growth curve by subtracting the t_{50} of each individual growth curve
6 and dividing the resulting values by the width of the growth curve (Eq. 2).

$$\Delta t_{50_i} = \frac{t_{50_i} - t_{50_{OD}}}{width_{OD}}$$

[2]

11 The fitting parameters were then mean-centered and used as inputs for hierarchical
12 principal components analysis (H-PCA, (61)). As a first step for H-PCA, PCA was
13 carried out on the corrected amplitude, the corrected 'half-life' and the width. To
14 account for the missing values introduced by employing cut-off values, the Non-linear
15 Iterative Partial Least Squares (NIPALS)-PCA algorithm was used. The three
16 resulting scores blocks were normalized by division by their highest values to give
17 each 'scores block' equal importance and used as input variables for a second-level
18 PCA.

1 RESULTS

2

3 **Time Resolved Metabolic Footprinting (TReF) provides additional biological** 4 **information compared to single time-point analysis**

5 Initially, we monitored changes in Luria broth culture supernatant during the growth of
6 the widely studied Gram-negative bacteria *Escherichia coli* (wild type MG1655) and
7 *Pseudomonas aeruginosa* (wild types PA01, PA14 and the leucine auxotroph
8 PA0381, which was derived from PA01 (17)). Additionally, growth of PA01 in a
9 defined medium (SCFM) (46) was compared. The ¹H NMR spectra showed a
10 complex mixture of small molecules, the majority of which could be readily assigned
11 by comparison of their multiplicity and chemical shift to published or online values
12 (Table 1). There were also a smaller number of resonances, which we have not yet
13 assigned (0.91d, 1.07d, 1.19m, 1.27m, 1.36d, 2.69m, 3.81s, 5.85d, 5.88d, 6.03d,
14 6.08d, 6.15d, 6.30d, 6.86m).

15

16 Over the course of growth there were major changes in the metabolite composition of
17 the growth media. This is illustrated in Fig. 1A, which shows the chemical shift region
18 from 2 to 4 ppm of one LB grown culture of *P. aeruginosa* PA01 over time. At
19 compound level, TReF revealed differences in the rates of uptake of individual
20 compounds, as shown for three amino acids in a *P. aeruginosa* PA01 LB cultures.
21 Alanine was taken up first from the medium, followed by threonine and then leucine
22 (Fig. 1B). This clear time separation shows different modes of compound utilization
23 during growth, and this differential compound utilization was observed for multiple
24 compounds and in all investigated isolates. Further, the order in which compounds
25 were utilized varied, but was reproducible at isolate level. These differences would

1 have been missed by single time-point profiling at 12 or 24 h and clearly indicate that
2 comparative metabolomics would benefit from the application of TReF-based
3 approaches, as differences can be highly growth-phase dependent.

4
5 Figure 2 provides a summary of the changes that were observed in the investigated
6 cultures over time. Fig. 2A-E is a heatmap representation of averaged difference
7 spectra depicting both uptake and secretion at compound level, clearly showing
8 patterns of metabolite secretion and uptake that differed greatly between the different
9 strains and media. Four different modes were identified. a) *Constant depletion*: the
10 majority of metabolites in the medium decreased constantly over time (e.g. Fig. 1,
11 Fig. 3B). b) *Transient excretion, followed by depletion*: some compounds (e.g.
12 acetate, Fig. 2F) were excreted during one growth phase and taken up during
13 another. c) *Transient depletion, followed by excretion*: all *Pseudomonas* strains first
14 took up formate, only to excrete it at later time-points (Fig. 2H). d) *Constant*
15 *excretion*: some compounds increased in a sigmoid fashion, e.g. an as-yet
16 unassigned doublet resonance at δ 1.10 ppm (probable methyl group signal from an
17 organic acid, Fig. 2G). As shown in Fig. 2, the growth medium itself has a large
18 influence on the metabolite utilization and depletion patterns, with major differences
19 between *P. aeruginosa* PA01 grown in LB and in SCFM. The uptake behavior at the
20 compound level is summarized in Fig. 2 and Table 2. Based on these first
21 observations, the differences in compound utilization and excretion were further
22 investigated and are discussed below.

23

24 **Non-linear regression modeling can be used to describe metabolite utilization**
25 **over time**

1 Most of the NMR-detectable resonances decreased over the course of growth (Fig
2 2I,J). In order to further describe the changes in exometabolome composition over
3 time, the concentration changes of individual metabolites were modeled by
4 regression. Linear regression against time was a poor descriptor of metabolite
5 consumption. Most of the NMR resonance intensities did not describe a straight line
6 when plotted against time and thus each modeled variable usually contained an
7 unacceptable amount of fitting error (as an example, the dotted line in Fig. 3B shows
8 the linear fit of the pyroglutamate resonance at 2.40 ppm in one *P. aeruginosa* PA01
9 culture). Only about one-third of the fitted resonances had an R^2 value greater than
10 0.6. For many compounds, the change in the resonance intensities roughly mirrored
11 a growth curve and thus more closely resembled a straight line when plotted against
12 OD (data not shown). The fits were indeed slightly improved when cell density
13 (OD_{600}) rather than time was used as the X variable: about half the fitted resonances
14 had R^2 values bigger than 0.6. However, the average correlation across all
15 resonances was still poor for both time and OD ($R=0.48$ for time, 0.56 for OD).
16 Instead, fits were significantly improved by using an appropriate non-linear model. A
17 bacterial growth curve typically describes a sigmoid shape over time. Though the
18 intensities of most NMR resonances did not exactly mirror this growth curve, they did
19 decrease in a sigmoid fashion. Consequently, fitting sigmoid curves to the evolution
20 of the resonances over time markedly decreased errors for 'real' peaks as opposed
21 to noise (solid line in Fig. 3B). Even after imposing stringent cut-off values for fit (see
22 methods), the dataset still contained about two-thirds of the resonances. Non-linear
23 fitting is well suited to study media depletion, but was less useful for secreted
24 metabolites.

25

1 For the data successfully fitted by non-linear modeling, the time course of each
2 metabolite resonance was described by four parameters (Fig. 3A). Three parameters
3 summarize the uptake characteristics for each metabolite: the relative decrease of
4 the resonance with time (amplitude); the time of uptake (t_{50}); and the duration of
5 uptake (width). The fourth parameter, the offset, i.e. the intensity at the start of the
6 experiment, does not represent meaningful information in this case, as we used
7 difference spectra for the analysis. Hence, the offset was zero (for the original data)
8 or close to zero (fitted data).

9

10 **Uptake window plots visualize compound utilization**

11 The parameters of the sigmoid equation can be used to obtain physiological
12 information for individual compounds. Both the t_{50} and the width are in units of time
13 with the t_{50} defining the time point at which the amplitude has reached its half-way
14 point, i.e. when half of the compound has been utilized. The width is defined as the
15 time that elapses for the exponent of e to go from 1 to -1 (see methods) and roughly
16 translates to the duration in which the compound is taken up at the maximum rate,
17 and thus defines a time span or “uptake window” for any fitted compound / resonance
18 lying around the compound t_{50} value (Figure 3). These ‘uptake windows’ can be
19 projected onto the OD_{600} growth curves of the individual strains to visualize
20 differential compound uptake. Figures 4A-D show the projections of the uptake
21 windows of seven compounds (alanine, leucine, threonine, asparagine, valine,
22 succinate, and the disaccharide trehalose) onto the growth curves of the *E. coli* and
23 the three *P. aeruginosa* strains for LB. Each circle represents the t_{50} value of one
24 compound for one biological replicate with the bars on either side representing the
25 width of the same compound.

1

2 These uptake window plots illustrate how TReF is able to elucidate similarities in and
3 difference of compound utilization of strains, summarized with a single plot. Not only
4 did the uptake windows differ dramatically for the individual metabolites, but there
5 was very clear separation between them – i.e. the different amino acids fell into
6 different ‘utilization groups’, which were separated along the growth curve. For
7 example, *P. aeruginosa* PA01 (grown in LB) did not take up threonine until after the
8 simultaneous depletion of alanine and asparagine. Leucine was then taken up after
9 threonine had been removed. This order was also observed for the two other
10 *P. aeruginosa* strains but was different in *E. coli*, with trehalose taken up before
11 alanine, and leucine not taken up at all.

12

13 Additionally, the plots provide evidence for significant differences between the three
14 *P. aeruginosa* strains. PA14 does not take up succinate in a sigmoidal fashion,
15 however the compound was quickly removed from the medium in all strains.
16 Interestingly, PA0381, originally derived from PA01, was shown to have lost its ability
17 to utilize trehalose. This loss of function could be a side effect of the leucine
18 auxotrophy causing a metabolic network rearrangement. However, a more
19 parsimonious explanation is that the non-specific mutagenesis used to obtain the
20 leucine auxotroph phenotype (53) also affected one of the genes necessary for
21 trehalose breakdown (the transporter or the trehalase).

22

23 **Transient changes in the exometabolome and metabolite excretion**

24 Apart from metabolite uptake, a large proportion of the detected resonances
25 transiently increased or decreased during growth in both LB and SCFM (Fig. 2). As a

1 positive confirmation, we detected acetate production by *E. coli*, a known example of
2 overflow metabolism. Acetate is a fermentation product that accumulates at high
3 growth rates, probably due to a rate bottleneck in aerobic metabolism (38); it was by
4 far the clearest example of overflow metabolism in our current study. When grown in
5 LB, all *Pseudomonas* strains transiently excreted the amino acids valine and
6 tyrosine. In PA01 cultures, a singlet resonance at 2.24 ppm (putatively assigned as
7 acetaldehyde) showed similar excretion dynamics to those of valine. Interestingly,
8 this was not observed for the other *Pseudomonas* strains. In contrast, formate (Fig
9 2H) was taken up from the medium during the first couple of hours of growth, but was
10 excreted in stationary phase. In addition to these transient changes, a number of
11 resonances increased proportionally to cell number over the course of growth,
12 including 6-hydroxynicotinate (all *Pseudomonas* strains), indole (*E. coli*), and uracil
13 (all strains).

14

15 **Compound utilization and excretion are dramatically influenced by the** 16 **constituents of the growth media**

17 It could be argued that the complexity of the responses we observed were partly
18 down to our using a complex and undefined growth medium. To that end, we
19 compared the exometabolome of *P. aeruginosa* PA01 grown in LB to that grown in
20 SCFM, a defined medium designed and shown to mimic conditions and utilization
21 dynamics in cystic fibrosis sputum (46). Even though the cell density (as OD₆₀₀) in
22 different media did not differ greatly (data not shown), the choice of growth medium
23 had a dramatic effect on the dynamics of the exometabolome, affecting both
24 compound uptake and excretion (Figures 2 and 4E,F). Concerning compound
25 utilization, a comparison of the uptake windows for selected amino acids in the two

1 media (Table 2 and Figure 4E,F) revealed several trends. Some amino acids, such
2 as lysine, phenylalanine and leucine, were taken up later from LB than SCFM, which
3 might hint at some sort of catabolite repression-like regulation in LB (see discussion).
4 In contrast, the uptake dynamics of alanine, glutamate or aspartate and arginine
5 were relatively unaffected as they were taken up at an early stage in both cultures. In
6 terms of compound secretion, many more resonances increased when PA01 was
7 grown in SCFM compared to LB. The transient increases in tyrosine and valine were
8 also not observed in SCFM, but other resonances (1.07 d, 2.51 and 2.53 s) were
9 observed to increase transiently. Finally, the pattern of formate change (transient
10 decrease, followed by increase) was even more pronounced in SCFM.

11

12 **Potential application of TReF as a functional genomics tool**

13 Pattern recognition algorithms like PCA are widely used for multivariate data to
14 visualize and summarize metabolic differences by dimension reduction. It was
15 possible to separate *E. coli* and all *P. aeruginosa* strains using PCA on stationary
16 phase samples and the approach very clearly showed the metabolites responsible for
17 the strain differences (Fig. 5). However, the plots also show how single time-point
18 profiling would miss the ‘big picture’, i.e. the metabolite concentration changes that
19 occur at other time-points. If, for example, the cultures were sampled at 12 h, valine
20 would appear to be excreted only by PA01 (Fig. 5E). In fact, PA14 and PA0381 also
21 excrete valine at earlier time-points. Had the exometabolome been sampled at 24 h
22 only, valine would appear to be utilized by all three *P. aeruginosa* strains to roughly
23 the same extent. Additionally, the strains’ leucine (Fig. 5F) utilization would look
24 roughly equivalent after 12 h, whereas, in fact, leucine uptake was slower and had a
25 slightly greater amplitude in PA01 cultures. Of the discriminatory metabolites at 12 h,

1 only trehalose (Fig. 5D) would show the same qualitative difference between the
2 strain at all time-points. One advantage of the non-linear metabolite fitting is that the
3 fit parameters summarize key biological endpoints (e.g. compound uptake rates) in a
4 compact way. Thus, by using the fit parameters as input for the multivariate analyses,
5 it is possible to compare data in a principled way from different strains, which might
6 have slightly different growth rates, lag phase, etc. Naturally, each parameter could
7 be analyzed separately, but it is also possible to combine these in a single
8 hierarchical model (Fig. 5C).

9
10 As a test case for the resolution the TReF/H-PCA approach could offer, we analyzed
11 culture supernatants of two species (nine strains in total) of the closely related
12 *Burkholderia cepacia* complex. Single time-point profiling like that shown for
13 stationary phase (t=24h) samples only provided some possible species separation,
14 but with considerable overlap between the species groups (Fig. 6A, similar results for
15 other time-points, data not shown). An added complication for this data set was that
16 the strains showed large variations in growth rate, which were picked up by standard
17 multivariate methods. However, the non-linear H-PCA approach showed a separation
18 of *B. cepacia* and *B. cenocepacia* along PC1 (Fig. 6B). Thus, while 'standard'
19 footprinting based on single time-points may be adequate for showing large
20 metabolic differences, it failed to fully represent the subtle metabolic differences
21 between the Bcc strains, which required the non-linear fit data. (We also tested H-
22 PCA alone, i.e. a hierarchical model based on PCA for individual time-points without
23 any curve fitting, but this offered no advantages in comparison to analyzing single
24 time-points, and failed to separate the Bcc species; data not shown).

25

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

DISCUSSION

We have developed a time resolved metabolic footprinting approach for bacteria that should be widely applicable. Considering changes in the culture medium over the whole course of growth provides information that would be lost in a single time point analysis.

Bacteria show ‘multiauxic’ uptake behavior on complex media

TReF revealed differential compound uptake for all investigated strains, and for both a rich and a defined medium (LB and SCFM). The existence of a complex regulatory network leading to highly adaptable uptake dynamics is not surprising. In rich (or defined multi-compound) media, expression and translation of the transporter systems and catabolic pathways need to be controlled. The genomes of the *Pseudomonas* species group contain over 300 known or putative nutrient uptake systems (56). Expressing all inducible transporters and catabolic pathways at once will not be energetically favorable, and so a form of multiauxic growth and sequential compound uptake, like that observed here, is the likely outcome – although the extent of the differentiation between compound utilization classes during apparently exponential growth was surprising. A number of previous studies, albeit mostly not using rich media, have hinted at the complexity of the regulation at hand (e.g. 3, 19, 30).

Catabolite repression is a generic mechanism for regulation of substrate usage, and, for example, succinate represses arginine catabolism in *Pseudomonas aeruginosa* (42). ArgR controls the aerobic catabolism of arginine in *P. aeruginosa* (47), and also controls the levels of OprD, a porin for basic amino acids (44) and a serine

1 transporter (32). It is therefore logical that our data show that succinate depletion
2 precedes the utilization of not only arginine, but also a number of other amino acids
3 (Fig. 4). As a second example, lysine was depleted at an earlier growth phase in
4 SCFM than in LB. Lysine can be imported by the specific permease LysP (54), but
5 also by the putative basic amino acid ABC transporter PA5152-PA5155 (24).
6 Transposon mutants within this operon were severely impaired in growth on ornithine
7 as a single carbon source (24), so this transporter clearly contributes to *P.*
8 *aeruginosa*'s ability to use ornithine. Hence it is highly probable that the high
9 concentrations of ornithine in SCFM would induce expression of PA5152-PA5155,
10 thereby potentially simultaneously increasing the potential rate of lysine uptake.
11 These examples show how an untargetted approach can generate eminently testable
12 hypotheses.

13

14 **The influence of media composition on uptake and excretion**

15 In addition to utilization, we studied compound excretion. Various compounds like
16 acetate, valine and tyrosine were excreted transiently, whereas others like 6-hydroxy
17 nicotinic acid or indole constantly increased over the course of growth for *P.*
18 *aeruginosa* and *E. coli*, respectively. Formate had a particularly surprising utilization
19 profile, with depletion followed by subsequent excretion; the precise reason is not
20 clear at this moment. Compound excretion is a well-known phenomenon for
21 biotechnologically interesting compounds in bacteria like *Corynebacterium*
22 *glutamicum* (11, 40). A number of fundamental principles that lead to compound
23 excretion have been formulated (11). The obvious explanation for a compound
24 entering the culture medium is excretion of a product that bacteria "want" to excrete.
25 This is the case for signaling molecules like quorum sensing (QS) signals. Our data

1 show excretion of indole in *E. coli*, which was suggested to have extracellular
2 signaling properties (60). It should be noted that *P. aeruginosa* in particular is known
3 for producing a suite of QS metabolites, which might be expected to be visible in the
4 medium; the reason that we do not identify more QS-related changes is probably just
5 that NMR has relatively high detection limits. However the TReF principle would be
6 identical if using a more sensitive analytical platform, such as many techniques
7 based on mass spectrometry. Additionally, compounds might also be excreted
8 because of overflow metabolism, limited catabolism, and deregulated anabolism (11).
9 This “relief-valve”-function has previously been suggested for the aromatic amino
10 acid exporter (ArAE, formerly AaeAB) in *E. coli* (57). This transporter has recently
11 been functionally annotated in *P. aeruginosa* (24), so tyrosine could be excreted by
12 *P. aeruginosa* when grown in LB to relieve intracellular stress. Valine might be
13 excreted due to similar reasons by a so-far unidentified transporter. Interestingly,
14 tyrosine and valine were only excreted into LB, not SCFM. Finally, the increase of 6-
15 hydroxynicotinic acid in *P. aeruginosa* cultures is probably due to limited catabolism
16 of NAD or niacin, and has been used as a diagnostic marker of *P. aeruginosa*
17 infection (20).

18

19 **Species discrimination in the *Burkholderia cepacia* complex**

20 An important and general question is to what degree *phenotypic* metabolomic data is
21 informative about *genotype*, i.e. strain relatedness, as opposed to, say, ecotype,
22 which could be a convergent result of adaptation. Previous studies have used both
23 endo- and exometabolome profiling to address this in yeast and bacteria (33, 34, 48);
24 it is clearly a complex question, as metabolomic data have shown both apparent

1 clustering by ecotype, with additional genetic within-cluster separation, and also high
2 between-strain metabolic variability that mostly correlated with genotype divisions.
3
4 The *P. aeruginosa* and *E. coli* profiles were dramatically different, with the order of
5 uptake of specific metabolites reversed (Fig. 4). However this is perhaps not
6 surprising given these are very different organisms. We decided to carry out a more
7 realistic test: whether differences could still be observed for a set of much more
8 closely related bacteria. We chose two species of the Bcc (*Burkholderia cepacia* and
9 *Burkholderia cenocepacia*, represented here by 4 and 5 independent isolates
10 respectively) as a model comparison. The Bcc is a collection of genotypically distinct
11 but phenotypically similar species within the genus *Burkholderia* (13, 37). Some Bcc
12 members are opportunistic pathogens that can cause serious infections in patients
13 with chronic granulomatous disease (CGD) or cystic fibrosis (35, 37), while some are
14 found in the rhizosphere of important crops like maize and can protect these plants
15 from fungal infection (5). Species-level identification of Bcc members is difficult and
16 species are still frequently misidentified, especially using commercial identification
17 systems (31). Single-gene phylogenies showed that *B. cepacia* and *B. cenocepacia*
18 are especially similar genetically even within the Bcc (36, 55), meaning these two
19 species formed a stringent test for our approach. The non-linear fitting TReF
20 approach was nevertheless able to discriminate the isolates into species groups. It
21 cannot be concluded at this point that this could therefore be used as a general tool
22 for Bcc taxonomy (more isolates would need to be tested to derive robust
23 conclusions about metabolic differences in these species), but serves as a proof-of-
24 principle that our approach of modelling the full time course of metabolic changes

1 can provide additional and biologically meaningful data over single timepoint
2 analyses.

3

4 **Conclusion**

5 We have shown potential microbiological applications of time-dependent
6 exometabolome profiling. Modeling of the amino acid utilization of *E. coli* and
7 *P. aeruginosa* demonstrated an unexpected complexity of regulation. In addition, the
8 same approach was shown to have clear advantages over single-time point profiling.
9 TReF allowed comparison of the physiology of bacteria in different nutritional
10 environments, and our data clearly demonstrates that marked differences could be
11 found. We believe time-dependent metabolic profiling could be a valuable addition to
12 the fields of bacterial physiology, functional genomics, and as a tool for strain
13 comparison, both as a complement to traditional taxonomies, and also for
14 investigating properties such as strain-specific virulence. It is still likely that single-
15 time-point metabolic footprinting will be preferred for many studies, simply because it
16 requires analysis of fewer replicates. We see TReF having a complementary role, for
17 in-depth phenotype analysis of a smaller number of strains – which might well, for
18 instance, have been initially selected through single-time-point profiling.

19

20

21 **Acknowledgements**

22 VB was funded by a divisional studentship.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

REFERENCES

1. **Allen, J., H. M. Davey, D. Broadhurst, J. K. Heald, J. J. Rowland, S. G. Oliver, and D. B. Kell.** 2003. High-throughput classification of yeast mutants for functional genomics using metabolic footprinting. *Nat Biotechnol* **21**:692-696.
2. **Allen, J., H. M. Davey, D. Broadhurst, J. J. Rowland, S. G. Oliver, and D. B. Kell.** 2004. Discrimination of modes of action of antifungal substances by use of metabolic footprinting. *Appl Environ Microbiol* **70**:6157-6165.
3. **Baev, M. V., D. Baev, A. J. Radek, and J. W. Campbell.** 2006. Growth of *Escherichia coli* MG1655 on LB medium: determining metabolic strategy with transcriptional microarrays. *Appl Microbiol Biotechnol* **71**:323-328.
4. **Beckonert, O., H. C. Keun, T. M. Ebbels, J. Bundy, E. Holmes, J. C. Lindon, and J. K. Nicholson.** 2007. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. *Nat Protoc* **2**:2692-2703.
5. **Bevivino, A., V. Peggion, L. Chiarini, S. Tabacchioni, C. Cantale, and C. Dalmastri.** 2005. Effect of *Fusarium verticillioides* on maize-root-associated *Burkholderia cenocepacia* populations. *Res Microbiol* **156**:974-983.
6. **Bino, R. J., R. D. Hall, O. Fiehn, J. Kopka, K. Saito, J. Draper, B. J. Nikolau, P. Mendes, U. Roessner-Tunali, M. H. Beale, R. N. Trethewey, B. M. Lange, E. S. Wurtele, and L. W. Sumner.** 2004. Potential of metabolomics as a functional genomics tool. *Trends Plant Sci* **9**:418-425.

- 1 7. **Bolten, C. J., P. Kiefer, F. Letisse, J. C. Portais, and C. Wittmann.** 2007.
2 Sampling for metabolome analysis of microorganisms. *Anal Chem* **79**:3843-
3 3849.
- 4 8. **Buckstein, M. H., J. He, and H. Rubin.** 2008. Characterization of nucleotide
5 pools as a function of physiological state in *Escherichia coli*. *J Bacteriol*
6 **190**:718-726.
- 7 9. **Bundy, J. G., B. Papp, R. Harmston, R. A. Browne, E. M. Clayson, N.**
8 **Burton, R. J. Reece, S. G. Oliver, and K. M. Brindle.** 2007. Evaluation of
9 predicted network modules in yeast metabolism using NMR-based metabolite
10 profiling. *Genome Res* **17**:510-519.
- 11 10. **Bundy, J. G., T. L. Willey, R. S. Castell, D. J. Ellar, and K. M. Brindle.** 2005.
12 Discrimination of pathogenic clinical isolates and laboratory strains of *Bacillus*
13 *cereus* by NMR-based metabolomic profiling. *FEMS Microbiol Lett* **242**:127-136.
- 14 11. **Burkovski, A., and R. Kramer.** 2002. Bacterial amino acid transport proteins:
15 occurrence, functions, and significance for biotechnological applications. *Appl*
16 *Microbiol Biotechnol* **58**:265-274.
- 17 12. **Canelas, A., C. Ras, P. ten, Angela, D. van, Jan, J. Heijnen, and G. van,**
18 **Walter.** 2008. Leakage-free rapid quenching technique for yeast metabolomics.
19 *Metabolomics* **4**:226-239.
- 20 13. **Chiarini, L., A. Bevivino, C. Dalmastrì, S. Tabacchioni, and P. Visca.** 2006.
21 *Burkholderia cepacia* complex species: health hazards and biotechnological
22 potential. *Trends Microbiol* **14**:277-286.
- 23 14. **Cui, Q., I. A. Lewis, A. D. Hegeman, M. E. Anderson, J. Li, C. F. Schulte, W.**
24 **M. Westler, H. R. Eghbalnia, M. R. Sussman, and J. L. Markley.** 2008.

- 1 Metabolite identification via the Madison Metabolomics Consortium Database.
2 Nat Biotechnol **26**:162-164.
- 3 15. **de Koning, W., and K. van Dam.** 1992. A method for the determination of
4 changes of glycolytic metabolites in yeast on a subsecond time scale using
5 extraction at neutral pH. Anal Biochem **204**:118-123.
- 6 16. **Ebbels, T. M., H. C. Keun, O. P. Beckonert, M. E. Bollard, J. C. Lindon, E.**
7 **Holmes, and J. K. Nicholson.** 2007. Prediction and classification of drug
8 toxicity using probabilistic modeling of temporal metabolic data: the consortium
9 on metabonomic toxicology screening approach. J Proteome Res **6**:4407-4422.
- 10 17. **Fyfe, J. A., and J. R. Govan.** 1980. Alginate synthesis in mucoid *Pseudomonas*
11 *aeruginosa*: a chromosomal locus involved in control. J Gen Microbiol **119**:443-
12 450.
- 13 18. **Goodacre, R., S. Vaidyanathan, W. B. Dunn, G. G. Harrigan, and D. B. Kell.**
14 2004. Metabolomics by numbers: acquiring and understanding global metabolite
15 data. Trends Biotechnol **22**:245-252.
- 16 19. **Gschaedler, A., N. Thi Le, and J. Boudrant.** 1994. Glucose and acetate
17 influences on the behavior of the recombinant strain *Escherichia coli* HB 101
18 (GAPDH). J Ind Microbiol **13**:225-232.
- 19 20. **Gupta, A., M. Dwivedi, G. A. Nagana Gowda, A. Ayyagari, A. A. Mahdi, M.**
20 **Bhandari, and C. L. Khetrapal.** 2005. ¹H NMR spectroscopy in the diagnosis of
21 *Pseudomonas aeruginosa*-induced urinary tract infection. NMR Biomed **18**:293-
22 299.
- 23 21. **Hacker, J., and J. B. Kaper.** 2000. Pathogenicity islands and the evolution of
24 microbes. Annu Rev Microbiol **54**:641-679.

- 1 22. **Hocquette, J. F.** 2005. Where are we in genomics? *J Physiol Pharmacol* **56**
2 **Suppl 3**:37-70.
- 3 23. **Holmes, E., F. W. Bonner, B. C. Sweatman, J. C. Lindon, C. R. Beddell, E.**
4 **Rahr, and J. K. Nicholson.** 1992. Nuclear magnetic resonance spectroscopy
5 and pattern recognition analysis of the biochemical processes associated with
6 the progression of and recovery from nephrotoxic lesions in the rat induced by
7 mercury(II) chloride and 2-bromoethanamine. *Mol Pharmacol* **42**:922-930.
- 8 24. **Johnson, D. A., S. G. Tetu, K. Phillippy, J. Chen, Q. Ren, and I. T. Paulsen.**
9 2008. High-throughput phenotypic characterization of *Pseudomonas aeruginosa*
10 membrane transport genes. *PLoS Genet* **4**:e1000211.
- 11 25. **Kaderbhai, N. N., D. I. Broadhurst, D. I. Ellis, R. Goodacre, and D. B. Kell.**
12 2003. Functional genomics via metabolic footprinting: monitoring metabolite
13 secretion by *Escherichia coli* tryptophan metabolism mutants using FT-IR and
14 direct injection electrospray mass spectrometry. *Comp. Funct. Genom.* **4**:376-
15 391.
- 16 26. **Kell, D. B.** 2006. Systems biology, metabolic modelling and metabolomics in
17 drug discovery and development. *Drug Discov Today* **11**:1085-1092.
- 18 27. **Kell, D. B., M. Brown, H. M. Davey, W. B. Dunn, I. Spasic, and S. G. Oliver.**
19 2005. Metabolic footprinting and systems biology: the medium is the message.
20 *Nat Rev Microbiol* **3**:557-565.
- 21 28. **Kell, D. B., and S. G. Oliver.** 2004. Here is the evidence, now what is the
22 hypothesis? The complementary roles of inductive and hypothesis-driven
23 science in the post-genomic era. *Bioessays* **26**:99-105.

- 1 29. **Konstantinidis, K. T., A. Ramette, and J. M. Tiedje.** 2006. The bacterial
2 species definition in the genomic era. *Philos Trans R Soc Lond B Biol Sci*
3 **361**:1929-1940.
- 4 30. **Lee, R., A. S. Ptolemy, L. Niewczas, and P. Britz-McKibbin.** 2007. Integrative
5 metabolomics for characterizing unknown low-abundance metabolites by
6 capillary electrophoresis-mass spectrometry with computer simulations. *Anal*
7 *Chem* **79**:403-415.
- 8 31. **LiPuma, J. J.** 2007. Update on *Burkholderia* nomenclature and resistance. *Clin.*
9 *Microbiol. Newsletter* **29**:65-69.
- 10 32. **Lu, C. D., Z. Yang, and W. Li.** 2004. Transcriptome analysis of the ArgR
11 regulon in *Pseudomonas aeruginosa*. *J Bacteriol* **186**:3855-3861.
- 12 33. **Mackenzie, D. A., M. Defernez, W. B. Dunn, M. Brown, L. J. Fuller, S. R. de**
13 **Herrera, A. Gunther, S. A. James, J. Eagles, M. Philo, R. Goodacre, and I.**
14 **N. Roberts.** 2008. Relatedness of medically important strains of
15 *Saccharomyces cerevisiae* as revealed by phylogenetics and metabolomics.
16 *Yeast* **25**:501-512.
- 17 34. **Maharjan, R. P., and T. Ferenci.** 2005. Metabolomic diversity in the species
18 *Escherichia coli* and its relationship to genetic population structure.
19 *Metabolomics* **1**:235-242.
- 20 35. **Mahenthiralingam, E., A. Baldwin, and C. G. Dowson.** 2008. *Burkholderia*
21 *cepacia* complex bacteria: opportunistic pathogens with important natural
22 biology. *J Appl Microbiol* **104**:1539-1551.
- 23 36. **Mahenthiralingam, E., J. Bischof, S. K. Byrne, C. Radomski, J. E. Davies, Y.**
24 **Av-Gay, and P. Vandamme.** 2000. DNA-Based diagnostic approaches for
25 identification of *Burkholderia cepacia* complex, *Burkholderia vietnamiensis*,

- 1 *Burkholderia multivorans*, *Burkholderia stabilis*, and *Burkholderia cepacia*
2 genomovars I and III. J Clin Microbiol **38**:3165-3173.
- 3 37. **Mahenthiralingam, E., T. A. Urban, and J. B. Goldberg.** 2005. The
4 multifarious, multireplicon *Burkholderia cepacia* complex. Nat Rev Microbiol
5 **3**:144-156.
- 6 38. **Majewski, R. A., and M. M. Domach.** 1990. Simple constrained-optimization
7 view of acetate overflow in *E. coli*. Biotechnol Bioeng **35**:732-738.
- 8 39. **Majors, P. D., J. S. McLean, and J. C. Scholten.** 2008. NMR bioreactor
9 development for live in-situ microbial functional analysis. J Magn Reson
10 **192**:159-166.
- 11 40. **Mapelli, V., L. Olsson, and J. Nielsen.** 2008. Metabolic footprinting in
12 microbiology: methods and applications in functional genomics and
13 biotechnology. Trends Biotechnol **26**:490-497.
- 14 41. **Mas, S., S. G. Villas-Boas, M. E. Hansen, M. Akesson, and J. Nielsen.** 2007.
15 A comparison of direct infusion MS and GC-MS for metabolic footprinting of
16 yeast mutants. Biotechnol Bioeng **96**:1014-1022.
- 17 42. **Mercenier, A., J. P. Simon, D. Haas, and V. Stalon.** 1980. Catabolism of L-
18 arginine by *Pseudomonas aeruginosa*. J Gen Microbiol **116**:381-389.
- 19 43. **Nicholson, J. K., J. Connelly, J. C. Lindon, and E. Holmes.** 2002.
20 Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev
21 Drug Discov **1**:153-161.
- 22 44. **Ochs, M. M., C. D. Lu, R. E. Hancock, and A. T. Abdelal.** 1999. Amino acid-
23 mediated induction of the basic amino acid-specific outer membrane porin OprD
24 from *Pseudomonas aeruginosa*. J Bacteriol **181**:5426-5432.

- 1 45. **Oliver, S. G., M. K. Winson, D. B. Kell, and F. Baganz.** 1998. Systematic
2 functional analysis of the yeast genome. *Trends Biotechnol* **16**:373-378.
- 3 46. **Palmer, K. L., L. M. Aye, and M. Whiteley.** 2007. Nutritional cues control
4 *Pseudomonas aeruginosa* multicellular behavior in cystic fibrosis sputum. *J*
5 *Bacteriol* **189**:8079-8087.
- 6 47. **Park, S. M., C. D. Lu, and A. T. Abdelal.** 1997. Cloning and characterization of
7 *argR*, a gene that participates in regulation of arginine biosynthesis and
8 catabolism in *Pseudomonas aeruginosa* PAO1. *J Bacteriol* **179**:5300-5308.
- 9 48. **Pope, G. A., D. A. MacKenzie, M. Defernez, M. A. Aroso, L. J. Fuller, F. A.**
10 **Mellon, W. B. Dunn, M. Brown, R. Goodacre, D. B. Kell, M. E. Marvin, E. J.**
11 **Louis, and I. N. Roberts.** 2007. Metabolic footprinting as a tool for
12 discriminating between brewing yeasts. *Yeast* **24**:667-679.
- 13 49. **Raamsdonk, L. M., B. Teusink, D. Broadhurst, N. S. Zhang, A. Hayes, M. C.**
14 **Walsh, J. A. Berden, K. M. Brindle, D. B. Kell, J. J. Rowland, H. V.**
15 **Westerhoff, D. van, K, and S. G. Oliver.** 2001. A functional genomics strategy
16 that uses metabolome data to reveal the phenotype of silent mutations. *Nat*
17 *Biotechnol* **19**:45-50.
- 18 50. **Rahme, L. G., M. W. Tan, L. Le, S. M. Wong, R. G. Tompkins, S. B.**
19 **Calderwood, and F. M. Ausubel.** 1997. Use of model plant hosts to identify
20 *Pseudomonas aeruginosa* virulence factors. *Proc Natl Acad Sci U S A*
21 **94**:13245-13250.
- 22 51. **Ryan, D., and K. Robards.** 2006. Metabolomics: The greatest omics of them
23 all? *Anal Chem* **78**:7954-7958.
- 24 52. **Sariyar-Akbulut, B., A. Salman-Dilgimen, S. Ceylan, S. Perk, A. A. Denizci,**
25 **and D. Kazan.** 2008. Preliminary phenotypic characterization of newly isolated

- 1 halophilic microorganisms by footprinting: a rapid metabolome analysis. Arch
2 Microbiol **189**:19-26.
- 3 53. **Stanisich, V., and B. W. Holloway.** 1969. Conjugation in *Pseudomonas*
4 *aeruginosa*. Genetics **61**:327-339.
- 5 54. **Steffes, C., J. Ellis, J. Wu, and B. P. Rosen.** 1992. The *lysP* gene encodes the
6 lysine-specific permease. J Bacteriol **174**:3242-3249.
- 7 55. **Tabacchioni, S., L. Ferri, G. Manno, M. Mentasti, P. Cocchi, S. Campana, N.**
8 **Ravenni, G. Taccetti, C. Dalmastri, L. Chiarini, A. Bevivino, and R. Fani.**
9 2008. Use of the *gyrB* gene to discriminate among species of the *Burkholderia*
10 *cepacia* complex. FEMS Microbiol Lett **281**:175-182.
- 11 56. **Tamber, S., and R. E. Hancock.** 2003. On the mechanism of solute uptake in
12 *Pseudomonas*. Front Biosci **8**:s472-83.
- 13 57. **Van Dyk, T. K., L. J. Templeton, K. A. Cantera, P. L. Sharpe, and F. S.**
14 **Sariaslani.** 2004. Characterization of the *Escherichia coli* AaeAB efflux pump: a
15 metabolic relief valve? J Bacteriol **186**:7196-7204.
- 16 58. **Viant, M. R., J. G. Bundy, C. A. Pincetich, J. S. de Ropp, and R. S.**
17 **Tjeerdema.** 2005. NMR-derived developmental metabolic trajectories: an
18 approach for visualizing the toxic actions of trichloroethylene during
19 embryogenesis. Metabolomics **1**:149-158.
- 20 59. **Villas-Boas, S. G., and P. Bruheim.** 2007. Cold glycerol-saline: the promising
21 quenching solution for accurate intracellular metabolite analysis of microbial
22 cells. Anal Biochem **370**:87-97.
- 23 60. **Wang, D., X. Ding, and P. N. Rather.** 2001. Indole can act as an extracellular
24 signal in *Escherichia coli*. J Bacteriol **183**:4210-4216.

- 1 61. **Westerhuis, J. A., T. Kourti, and J. F. MacGregor.** 1998. Analysis of
2 multiblock and hierarchical PCA and PLS models. *Journal of Chemometrics*
3 **12**:301-321.
- 4 62. **Winder, C. L., W. B. Dunn, S. Schuler, D. Broadhurst, R. Jarvis, G. M.**
5 **Stephens, and R. Goodacre.** 2008. Global metabolic profiling of *Escherichia*
6 *coli* cultures: an evaluation of methods for quenching and extraction of
7 intracellular metabolites. *Anal Chem* **80**:2939-2948.

8

9

1 TABLES AND FIGURE LEGENDS

2
3

4 Table 1. List of assigned NMR-visible resonances in LB (note that the metabolites
5 listed here may have other resonances: table includes only the most
6 characteristic and well-resolved resonances). Resonances in bold font were
7 used for non-linear fitting of compounds.

Compound	Assigned resonance frequency (ppm)					
Acetate ^a	1.92					
Acetaldehyde ^a	2.24					
Adenosine ^a	6.08	8.26	8.34			
Alanine ^a	1.48	3.79				
Arginine ^a	1.69	1.73	1.75	1.91	3.25	3.78
Asparagine ^b	1.72	2.86	2.96	4.00		
Aspartate ^a	2.68	2.82	3.91			
Formate ^a	8.46					
Glucose ^a	3.39	5.24				
Glutamate ^a	2.07	2.35	3.74			
Glycine ^a	3.57					
Glycine-betaine ^a	3.27	3.90				
Histidine (not fitted) ^a	3.11	3.14	3.31	7.07	7.88	
6-hydroxynicotinate ^b	6.62	8.07				
Indole ^d	6.61	7.18	7.27	7.42	7.56	7.72
Isoleucine ^a	0.94	1.01	1.25	1.26	3.68	3.74
Lactate ^c	1.33	4.12				
Leucine ^a	0.96	0.97	1.72	3.74		
Lysine ^a	1.46	1.48	1.73	1.89	1.91	3.03
Methionine ^a	2.12	2.14	2.65			
Methionine-S-oxide ^b	2.74	2.76	2.93			
Nicotinic acid ^a	8.61	8.94				
Pyrimidine nucleotide ^a	5.91					
Ornithine ^c	3.81					
Phenylalanine ^a	3.11	3.28	4.01	7.33	7.39	7.43
Pyroglutamate ^b	2.06	2.39	2.42	2.51	7.98	
Serine ^a	3.79	3.85	3.96			
Succinate ^b	2.41					
Threonine ^a	1.33	3.59	4.26			

Trehalose ^a	3.46	3.65	3.83	3.86	3.88	5.20
Tryptophan ^b	3.31	7.29	7.55	7.74		
Tyrosine ^a	3.07	3.22	3.31	3.94	6.90	7.20
Uracil ^a	5.82	7.55				
Valine ^a	0.99	1.05	2.28	3.62		
Unassigned metabolite (potential quinolone).	7.68	8.10				

- 1 a: observed in both LB and SCFM.
- 2 b: observed in LB only.
- 3 c: observed in SCFM only.
- 4 d: observed for *E. coli* only (not tested in SCFM).

1 Table 2. Comparison of fitted metabolite t_{50} values (h) for *P. aeruginosa* PA01 grown
 2 in LB and SCFM.
 3

	LB	SCFM	Difference ^a
Tyrosine	14.8	6.5	-8.3
Valine	15.8	8.5	-7.3
Phenylalanine	8.8	5.0	-3.8
Lysine	11.3	8.0	-3.3
Leucine	9.6	7.0	-2.5
Isoleucine	8.1	7.0	-1.2
Aspartate	3.1	2.2	-0.9
Arginine	4.0	3.5	-0.5
Glycine	5.3	5.0	-0.3
Glutamate	2.9	2.8	-0.2
Alanine	3.5	3.4	-0.1
Serine	2.7	4.3	1.6
Threonine	5.8	7.7	2.0
Asparagine	2.3	not observed	-
Methionine	not utilized	11.8	-
Ornithine	not observed	4.0	-
Tryptophan	4.7	not observed	-

4 a: 'Difference' refers to difference between t_{50} in SCFM compared to LB medium, i.e.
 5 the lower the value, the earlier metabolite was taken up in SCFM compared to LB.
 6
 7
 8

1
2 Figure 1. A: section of 600 MHz ^1H NMR spectra (4—2 ppm) for a single *P.*
3 *aeruginosa* PA01 culture over a growth curve. Time-specific metabolic changes are
4 clearly seen. B: single compound utilization data for three selected metabolites for *P.*
5 *aeruginosa* PA01. Error bars = SEM (n = 4).

6
7
8 Figure 2: Metabolite changes in different media and different strains across the
9 course of growth. Heatmaps (panels A – E): each row represents a metabolite, or a
10 peak from an as-yet unassigned metabolite. Blue represents decrease in
11 concentration, and red represents increase in concentration. Note that panels B – E
12 can be directly compared visually, but the metabolites in panel A do not line up
13 directly with B – E. Row for metabolite ‘6HN / indole’ represents 6-hydroxynicotinate
14 for *P. aeruginosa* strains, and indole for *E. coli*.

15 A: *P. aeruginosa* PA01, synthetic cystic fibrosis medium.

16 B: *P. aeruginosa* PA01, LB.

17 C: *P. aeruginosa* PA14, LB.

18 D: *P. aeruginosa* PA0381, LB.

19 E: *E. coli*, LB.

20 Selected metabolites with different modes of utilization/production are then shown in
21 detail in the bottom half of the figure (error bars represent \pm SEM):

22 F: acetate, *E. coli*. Transient increase in metabolite concentration.

23 G: unassigned metabolite, *E. coli*, peak at δ 1.10 ppm. Steady increase in
24 metabolite concentration.

25 H: formate, *P. aeruginosa* PA01, LB. Transient decrease in metabolite
26 concentration followed by subsequent production.

1 An overall comparison of the different modes is then shown as pie charts
2 (percentage of assigned metabolites that change in some way during growth).

3 I: *P. aeruginosa* PA01, SCFM.

4 J: *P. aeruginosa* PA01, LB.

5

6

7

8 Figure 3. A: Schematic showing the parameters for non-linear curve fitting. B (inset):

9 curve fit for a representative compound (pyroglutamate) for *P. aeruginosa*

10 PA01. Solid line indicates sigmoid fit; dotted line indicates much poorer linear

11 fit.

12

13

14 Figure 4. Uptake window plots for seven example compounds for all four bacterial

15 strains. Compound t_{50} is back-projected upon the actual culture growth curve,

16 i.e. all biological replicates are shown. The 'error bars' represent calculated

17 width (see Fig. 2 for illustration of t_{50} and width). Note that both abscissa (time)

18 and ordinate (OD_{600}) have been scaled such that growth curve maxima are set

19 at 100%, to facilitate comparison across different strains. A: *E. coli*. B: *P.*

20 *aeruginosa* PA01. C: *P. aeruginosa* PA14. D: *P. aeruginosa* PA0381. The

21 remaining two panels compare uptake windows for *P. aeruginosa* PA01 for

22 two different media, LB and synthetic cystic fibrosis medium (SCFM). Note

23 that glucose is plotted (not trehalose as for panel A), as glucose is higher

24 concentration in SCFM. E: F:

25

1

2 Figure 5. A: Principal components analysis for 12 h data, scores plot of axes 1 and 2.

3 Filled circles: *E. coli*. Empty circles: *P. aeruginosa* PA01. Empty triangles: *P.*
4 *aeruginosa* PA14. Empty squares: *P. aeruginosa* PA0381. PCs 1 and 2
5 explained 87% and 8% of the variance in the data, respectively.

6 B: loadings plot for analysis shown in A. Variables corresponding to assigned
7 metabolite bins for leucine, valine, and trehalose are labelled directly on the
8 plot.

9 C: Hierarchical principal components analysis of fitted time-course data. Figure
10 symbols are the same as for A. PCs 1 and 2 explained 50% and 33% of the
11 variance in the data, respectively.

12 D: Trehalose utilization during growth for four strains. Solid black line: *E. coli*.
13 Solid grey line: *P. aeruginosa* PA01. Dashed line (long dashes): *P. aeruginosa*
14 PA14. Dashed line (short dashes): *P. aeruginosa* PA0381.

15 E: Valine utilization during growth for four strains. Line styles as for D.

16 F: Leucine utilization during growth for four strains. Line styles as for D.

17

18

19 Figure 6. Comparison of single-timepoint and nonlinear fitted metabolite data for four
20 *Burkholderia cepacia* (unfilled symbols) and five *Burkholderia cenocepacia* (filled
21 symbols) isolates: principal components scores plots, axis 1 v axis 2. Different
22 symbol shapes represent different individual isolates.

23 A: Single-timepoint analysis does not discriminate all isolates into species.

24 PCs 1 and 2 explained 55% and 39% of the variance in the data, respectively.

1 B: Fitted metabolite data (TReF) shows that species are discriminated along
2 PC 1 across different isolates. PCs 1 and 2 explained 35% and 25% of the variance
3 in the data, respectively.

4











